Skip to content

Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients

The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Multiple Sclerosis

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01225289
Enrollment
36
Registered
2010-10-21
Start date
2009-10-31
Completion date
2014-01-31
Last updated
2014-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsing Remitting Multiple Sclerosis

Keywords

Multiple Sclerosis, Vitamin A, CD4-Positive T-Lymphocytes, Th1 Cells, Th2 Cells

Brief summary

The aim of this study is to study the comparison between the effects of supplementation with 25000 IU preformed vitamin A (retinyl palmitate) or placebo for 6 months on immune system and Th1/Th2 balance in patients with Multiple Sclerosis.

Detailed description

Multiple Sclerosis (MS) is a chronic inflammatory disease where Th1 like responses from myelin-specific CD4+ T cells, as secretion of pro-inflammatory IFN-g, are believed to play a major role in the pathogenesis. The myelin-specific T cells that mediate tissue destruction in MS are believed to become activated outside the central nervous system (CNS) in lymphoid tissue and when they cross the blood brain barrier they will re-encounter their antigen. Immune deviation is the redirection of the immune response from most often Th1 like responses to Th2 like responses, even though the opposite can also occur. Vitamin A (VA) or VA-like analogs known as retinoids, are potent hormonal modifiers of type 1 or type 2 responses but a definitive description of their mechanism(s) of action is lacking. High level dietary vitamin A enhances Th2 cytokine production and IgA responses, and is likely to decrease Th1 cytokine production. Retinoic acid inhibits IL 12 production in activated macrophages, and RA pretreatment of macrophages reduces IFNγ production and increases IL4 production in antigen primed CD4 T cells. Supplemental treatment with vitamin A or retinoic acid (RA) decreases IFNγ and increases IL5, IL10, and IL4 production. Thus, vitamin A deficiency biases the immune response in a Th1 direction, whereas high level dietary vitamin A may bias the response in a Th2 direction.

Interventions

DIETARY_SUPPLEMENTVitamin A

25000 IU/day (one capsule per day) Vitamin A for 6 months

DRUGPlacebo

1 capsule per day for six months

Sponsors

Tehran University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

Patients who have used interferon beta in last 3 months. Patients with 1-5 EDSS

Exclusion criteria

* Patients who have diseases which affect on Th1/Th2 balance such as asthma, active viral infections, and autoimmune diseases, OR * Patients who have allergy to vitamin A compounds, OR * Patients who have used vitamin supplements in last 3 months.

Design outcomes

Primary

MeasureTime frame
Difference Serum Levels of High-sensitive C-reactive Protein (Hs-CRP), Before and After of Supplementationfirst day and after 6 month

Secondary

MeasureTime frameDescription
Peripheral Blood Mononucleated Cells (PBMCs) Proliferation Assay (BrdU Colorimetric)first day and after 6 monthdifference of PBMCs proliferation stimulated with myelin oligodendrocyte glycoprotein (MOG), before and after of supplementation
Difference of IL-4 Levels in Supernatant of Peripheral Blood Mononucleated Cells (PBMCs) Stimulated With Phytohemagglutinin (PHA), Before and After of Supplementationfirst day and after 6 month
Difference of Retinol Binding Protein (RBP) / Transthyretin (TTR) Ratio, (Difference of RBP/ TTR Ratio), Before and After of Supplementationfirst day and after 6 month

Countries

Iran

Participant flow

Participants by arm

ArmCount
With Multiple Sclerosis/ Vitamin A
Patients with MS confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A
18
With Multiple Sclerosis/ Placebo
Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day
17
Total35

Baseline characteristics

CharacteristicWith Multiple Sclerosis/ PlaceboWith Multiple Sclerosis/ Vitamin ATotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
17 Participants18 Participants35 Participants
Age, Continuous31.05 years
STANDARD_DEVIATION 5.94
33.22 years
STANDARD_DEVIATION 7.26
32.17 years
STANDARD_DEVIATION 6.64
Region of Enrollment
Iran, Islamic Republic of
17 participants18 participants35 participants
Sex: Female, Male
Female
13 Participants13 Participants26 Participants
Sex: Female, Male
Male
4 Participants5 Participants9 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 181 / 17
serious
Total, serious adverse events
0 / 180 / 17

Outcome results

Primary

Difference Serum Levels of High-sensitive C-reactive Protein (Hs-CRP), Before and After of Supplementation

Time frame: first day and after 6 month

ArmMeasureValue (MEAN)Dispersion
With Multiple Sclerosis/ Vitamin ADifference Serum Levels of High-sensitive C-reactive Protein (Hs-CRP), Before and After of Supplementation1.2 mg/LStandard Error 0.5
With Multiple Sclerosis/ PlaceboDifference Serum Levels of High-sensitive C-reactive Protein (Hs-CRP), Before and After of Supplementation-0.6 mg/LStandard Error 0.4
p-value: <0.01Wilcoxon (Mann-Whitney)
Secondary

Difference of IL-4 Levels in Supernatant of Peripheral Blood Mononucleated Cells (PBMCs) Stimulated With Phytohemagglutinin (PHA), Before and After of Supplementation

Time frame: first day and after 6 month

ArmMeasureValue (MEAN)Dispersion
With Multiple Sclerosis/ Vitamin ADifference of IL-4 Levels in Supernatant of Peripheral Blood Mononucleated Cells (PBMCs) Stimulated With Phytohemagglutinin (PHA), Before and After of Supplementation2.5 pg/mlStandard Error 1.2
With Multiple Sclerosis/ PlaceboDifference of IL-4 Levels in Supernatant of Peripheral Blood Mononucleated Cells (PBMCs) Stimulated With Phytohemagglutinin (PHA), Before and After of Supplementation1.5 pg/mlStandard Error 1
Secondary

Difference of Retinol Binding Protein (RBP) / Transthyretin (TTR) Ratio, (Difference of RBP/ TTR Ratio), Before and After of Supplementation

Time frame: first day and after 6 month

ArmMeasureValue (MEAN)Dispersion
With Multiple Sclerosis/ Vitamin ADifference of Retinol Binding Protein (RBP) / Transthyretin (TTR) Ratio, (Difference of RBP/ TTR Ratio), Before and After of Supplementation0.2 ratioStandard Error 0.2
With Multiple Sclerosis/ PlaceboDifference of Retinol Binding Protein (RBP) / Transthyretin (TTR) Ratio, (Difference of RBP/ TTR Ratio), Before and After of Supplementation-0.4 ratioStandard Error 0.5
Secondary

Peripheral Blood Mononucleated Cells (PBMCs) Proliferation Assay (BrdU Colorimetric)

difference of PBMCs proliferation stimulated with myelin oligodendrocyte glycoprotein (MOG), before and after of supplementation

Time frame: first day and after 6 month

ArmMeasureValue (MEAN)Dispersion
With Multiple Sclerosis/ Vitamin APeripheral Blood Mononucleated Cells (PBMCs) Proliferation Assay (BrdU Colorimetric)-0.06 absorbance unitsStandard Error 0.08
With Multiple Sclerosis/ PlaceboPeripheral Blood Mononucleated Cells (PBMCs) Proliferation Assay (BrdU Colorimetric)-0.13 absorbance unitsStandard Error 0.09

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026